Cizzle Bio Inc. has commercially launched its CIZ1B Biomarker Blood Test for Lung Cancer for licensed healthcare providers in the Dallas-Fort Worth and San Antonio metropolitan areas. The laboratory-developed test is being performed by OmniHealth Diagnostics, a Clinical Laboratory Improvement Amendments certified laboratory that completed its own analytical validation of the assay.
The July 22 launch moves CIZ1B beyond laboratory preparation and limited targeted sales into a broader, although still geographically restricted, commercial rollout. Cizzle Bio holds the North American and Caribbean rights to the technology, while London-listed Cizzle Biotechnology Holdings plc (LSE: CIZ) owns the underlying diagnostic technology and is entitled to royalties under its licensing agreement.
The launch is commercially important because physicians in the two Texas markets can now establish accounts with OmniHealth Diagnostics, order the test and receive results through the laboratory’s portal. Clinically, however, CIZ1B remains an adjunctive biomarker test that must be interpreted alongside patient history, imaging and other findings. It is not a replacement for low-dose computed tomography, tissue biopsy or physician-directed diagnostic evaluation.
That distinction defines the central opportunity and risk. Cizzle Bio has achieved market availability through the U.S. laboratory-developed test pathway, but the next phase must demonstrate that the assay produces consistent results in contemporary U.S. populations and materially improves clinical decisions without generating avoidable false reassurance or unnecessary follow-up procedures.
What exactly has changed now that CIZ1B is available to Texas healthcare providers?
The most tangible change is that CIZ1B can now be ordered commercially through an established laboratory workflow rather than remaining a research assay or pre-launch product. Licensed providers in Dallas-Fort Worth and San Antonio must complete OmniHealth Diagnostics’ account and intake process before receiving access to its ordering portal.
The onboarding process covers specimen collection, shipping, portal access and laboratory logistics. Cizzle Bio has not publicly disclosed a standard list price, expected turnaround time, reimbursement code, payer coverage policy or forecast for initial test volumes. Those omissions do not diminish the launch milestone, but they make it too early to estimate the pace of revenue generation or routine clinical adoption.
Cizzle Bio selected Dallas-Fort Worth and San Antonio because of their large populations, physician networks and strategic relevance to the company’s commercial plans. Management expects to add other Clinical Laboratory Improvement Amendments certified laboratory partners and expand physician access across the United States in the coming months.
The expansion will not be automatic. Because CIZ1B is being offered as a laboratory-developed test, each laboratory performing the assay must establish and document the test’s performance within its own operating environment. Adding laboratory partners therefore requires technology transfer, analytical verification, staff training, quality controls and reliable specimen-handling procedures.
This model can ultimately support wider coverage, but it also means the rollout may proceed laboratory by laboratory. The quality and reproducibility of results across sites will be more consequential than the number of markets appearing on a commercial map.
Why does Clinical Laboratory Improvement Amendments certification not equal FDA approval?
CIZ1B has not been described as cleared or approved by the United States Food and Drug Administration. It is available as a laboratory-developed test performed within OmniHealth Diagnostics following validation under the laboratory’s quality system.
The Clinical Laboratory Improvement Amendments framework regulates laboratories performing human testing and establishes standards intended to support accurate, reliable and timely results. It does not mean that the Food and Drug Administration has independently reviewed CIZ1B’s clinical validity, assessed its benefit-risk profile or authorised it as a population-wide lung cancer screening test.
The regulatory distinction has particular relevance after the federal policy surrounding laboratory-developed tests changed. A federal district court vacated the Food and Drug Administration’s 2024 laboratory-developed test rule in March 2025, and the agency subsequently restored the earlier regulatory text in September 2025.
For Cizzle Bio, the current pathway enables commercial access without waiting for a conventional premarket clearance or approval. For physicians and payers, it places greater importance on the evidence supporting the assay, the validation performed by each laboratory and the clarity of the test report.
Cizzle Bio appropriately presents CIZ1B as a tool supporting clinical decision-making. A positive result does not establish that a patient has lung cancer, while a negative result should not independently exclude malignancy when imaging, symptoms or risk factors indicate that further investigation is necessary.
How mature is the evidence supporting the CIZ1B early lung cancer biomarker?
CIZ1B is a variant of the CIZ1 protein associated with altered splicing in lung cancer. Research originating at the University of York found that the biomarker exists in plasma as a stable complex involving a CIZ1 fragment and fibrinogen, allowing it to be measured using an enzyme-linked immunosorbent assay.
A peer-reviewed 2017 study in Clinical Biochemistry described the development of a sandwich immunoassay and reported that CIZ1B could distinguish stage I lung cancer from high-risk control groups. The researchers reported areas under the receiver operating characteristic curve above 0.9 in two retrospective cohorts, providing an encouraging foundation for continued development.
Cizzle Bio cites 95% sensitivity for stage I lung cancer and a 96% negative predictive value from earlier UK work. These figures are promising, but they should not be interpreted as universal performance estimates for every clinical population. Negative predictive value changes with disease prevalence, patient selection and the clinical setting in which a test is used.
Performance in a cohort containing patients with suspicious pulmonary nodules may therefore differ from performance in an asymptomatic screening population. Results may also vary among people with chronic obstructive pulmonary disease, pulmonary fibrosis, previous cancer, occupational exposures or other conditions capable of complicating lung cancer assessment.
The available evidence establishes a credible biomarker rationale and supports further clinical evaluation. It does not yet demonstrate that using CIZ1B in routine care improves survival, reduces unnecessary biopsies or safely decreases repeat imaging.
Cizzle Bio acknowledges that preliminary U.S. clinical validation data remain forthcoming from studies involving National Cancer Institute designated centres, including Moffitt Cancer Center and Mays Cancer Center at The University of Texas San Antonio Health Science Center.
What will the ongoing Moffitt and San Antonio studies need to establish?
The U.S. studies are important because laboratory accuracy and clinical usefulness are different questions. Analytical validation examines whether the assay measures its intended target consistently. Clinical validation evaluates how accurately the result identifies or excludes the relevant disease in a defined patient population.
Moffitt Cancer Center previously described a study intended to enrol 250 patients with identified lung nodules and follow participants for three years. The centre reported in January 2025 that 75 patients had been enrolled at that stage. This design could provide valuable information about how CIZ1B behaves in patients facing genuine diagnostic uncertainty rather than in carefully selected retrospective samples.
The evidence will be stronger if investigators report the full cohort characteristics, cancer prevalence, tumour stages, histological subtypes, assay thresholds and reference standards used to determine final diagnoses. Sensitivity must be considered alongside specificity, positive predictive value and the frequency of indeterminate results.
Subgroup performance will also matter. A commercially scalable lung cancer biomarker needs to work across different ages, smoking histories, ethnic groups, comorbid lung conditions and clinical settings. It will be particularly important to understand whether the test consistently detects different forms of non-small cell and small cell lung cancer.
Clinical utility requires another layer of evidence. Studies must eventually examine whether CIZ1B changes physician behaviour in a beneficial way, such as helping prioritise higher-risk nodules or supporting more appropriate follow-up. A technically accurate result is valuable, but adoption will be driven by whether that result improves decisions without adding another costly or confusing step to the pathway.
Can CIZ1B complement low-dose computed tomography without weakening established screening?
The U.S. Preventive Services Task Force recommends annual low-dose computed tomography for adults aged 50 to 80 who have at least a 20 pack-year smoking history and currently smoke or stopped within the previous 15 years. That recommendation remains the established screening pathway for the defined high-risk population.
CIZ1B’s more realistic near-term role is therefore complementary. It may be evaluated for patients with indeterminate lung nodules, screening-eligible individuals who do not complete low-dose computed tomography, people with additional occupational or environmental risk factors, and selected patients requiring surveillance.
The need is substantial. The American Cancer Society estimates that the United States will record approximately 229,410 new lung cancer cases and 124,990 deaths in 2026. Screening remains underused, while imaging frequently identifies nodules that are benign but require additional assessment.
A blood test that improves risk stratification could help clinicians decide which patients need faster imaging, specialist referral or biopsy. It could also reduce uncertainty for patients whose scans reveal nodules that cannot immediately be classified.
Yet the blood test should not be promoted as an easier substitute for low-dose computed tomography until prospective evidence supports that use. The risk of a false-negative result is especially important in early cancer detection because inappropriate reassurance could delay established diagnostic procedures. False-positive results could produce the opposite problem by increasing imaging, anxiety and invasive investigations.
CIZ1B’s commercial positioning is strongest when it adds information to existing pathways rather than competing with them prematurely.
Why will reimbursement and physician behaviour determine whether the Texas launch scales?
Commercial availability removes one barrier, but it does not guarantee payment or demand. Cizzle Bio has not announced broad Medicare coverage, private-payer policies or a dedicated reimbursement mechanism for the test.
Without coverage, providers may hesitate to order CIZ1B routinely, particularly if patients face significant out-of-pocket costs. Payers are likely to examine whether the assay changes management, reduces downstream expenditure and performs reliably in the populations for which reimbursement is requested.
A health-economic analysis presented alongside the 2025 American Society of Clinical Oncology annual meeting modelled potential Medicare savings of up to $518 million a year from incorporating CIZ1B into high-risk lung cancer screening. That figure is a modelled estimate based on assumptions about test performance, screening behaviour and downstream procedures. It is not evidence that those savings have already been achieved in practice.
Physician education will also shape adoption. Reports must communicate what a result means, what it does not mean and how it should affect the next clinical step. If interpretation is unclear, the test could add complexity rather than reduce it.
The initial Texas rollout can generate useful commercial evidence by showing how many practices complete onboarding, how frequently physicians order the test, which patients are selected and whether ordering becomes repeat behaviour. These operational metrics may ultimately matter as much as initial promotional interest.
What does the launch mean for Cizzle Biotechnology Holdings and investor sentiment?
Cizzle Biotechnology Holdings receives a 10% royalty on gross sales under the initial North American licensing agreement with Cizzle Bio. The listed company has disclosed guaranteed payments of $2.4 million through the end of 2026 and a further minimum of $3.5 million linked to an extension of the agreement from 2031, bringing aggregate guaranteed payments across the contract period to approximately $5.9 million.
The Texas launch converts the CIZ1B programme from a development and validation story into an early commercial execution test. Investors can now begin assessing actual ordering activity, laboratory expansion and royalty receipts rather than relying primarily on future launch expectations.
The company’s shares were indicated at around 1.98 pence on July 22, giving Cizzle Biotechnology Holdings a market capitalisation of approximately £8.39 million. The stock remained within a 52-week range of 1.20 pence to 3.90 pence.
London Stock Exchange analytics dated July 21 showed the shares down approximately 10.5% over one week and 24.5% over four weeks, despite being up about 33.7% over 52 weeks and 24.2% since the beginning of 2026. That pattern suggests that longer-term sentiment had improved while near-term momentum weakened before the full commercial launch announcement.
The decisive investor milestones will be the first meaningful sales figures, the timing of additional laboratory validations, evidence that guaranteed payments are received as scheduled and disclosure of recurring test volumes. Until those data arrive, the launch supports the commercial thesis but does not quantify it.
CIZ1B has crossed a genuine threshold by becoming orderable in two large Texas markets. The next threshold is harder: proving that physicians use it repeatedly, payers recognise its value, laboratories reproduce its performance and prospective U.S. studies confirm that the biomarker improves real clinical decisions.
